

Full Length Research Paper

Modified Chitosan-Clay nanocomposite As a drug delivery system Intercalation and *in vitro* release of Ibuprofen.

Rehab Abdeen^{1,*}, Nehal Salahuddin²

1 Associated professor, biology department, king Khalid university,

2. professor, Department of Chemistry, Polymer Research Group, Faculty of Science, Tanta University.

Correspondence Email: salahudin.nehal@yahoo.com.

Abstract: The present paper focused on the intercalation of ibuprofen into Unmodified sodium montmorillonite, chitosan and chitosan montmorillonite nanocomposites as a sustained release drug carrier. The intercalation compounds were characterized by X-ray diffraction (XRD), Infrared spectroscopy (IR), Thermogravimetric analysis (TGA), and transmission electron microscopy (TEM). The basal spacing of montmorillonite increased from 9.6 nm to 19.6 nm as indicate of intercalation of modified chitosan and ibuprofen between lamellar layers. UV spectroscopy was employed to monitor the *in vitro* drug release processes in both pH 5.4 and 7.8 solutions. And the experiment revealed that Ibuprofen was released from MMT, CS and Mod-CS/MMT steadily and pH dependent.

Keywords: Chitosan; Nanocomposite; Ibuprofen; controlled release.

Author(s) agree that this article remain permanently open access under the terms of the Creative Commons Attribution <http://creativecommons.org/licenses/by/4.0/>

Introduction

The need for safe, therapeutically effective, and patient compliant drug delivery systems continuously leads researchers to design novel tools and strategies. Clay minerals play a very crucial role in modulating drug delivery.

Ibuprofen (2-(p-isobutylphenyl) propionic acid) is a well-known drug that possesses **analgesic** (pain-relieving) and antipyretic (fever-reducing) properties. It is particularly known for its use in pain relief from arthritis.

Ibuprofen is a well-known hydrophobic oral non-steroidal anti-inflammatory drug (NSAID) [1], it has a wide spectrum of gastrointestinal side effects ranging from mild dyspepsia to gastric bleeding. The gastric irritation is mainly due to the free carboxylic acid group in the chemical formula [2]. Due to its short plasma half-life of 1–3 h following oral dosing and the gastric irritation, ibuprofen is an ideal candidate for preparing prolonged or controlled release drug products [2-10]. Since the property of reswelling is susceptible to the environmental pH, the incorporation of acid-sensitive drugs into the beads protects them from the gastric juice [11]. Therefore, drug-loaded alginate beads might provide these advantages for NSAIDs such as ibuprofen, which lead to gastric irritation. The formulation of ibuprofen as a controlled release dosage form of beads seems to be an important approach to overcome the potential problems in the gastrointestinal (GI) tract so as to achieve a reduction of the NSAID's adverse effects [12, 13].

Chitosan is a biocompatible, biodegradable, nontoxic, linear co-polymer polysaccharide, consisting of β (1-4)-linked 2-amino-2-deoxy-D-glucose (D-glucosamine) and 2-acetamido-2-deoxy-D-glucose (N-acetyl-D-glucosamine) units and has the structural similarity to cellulose (made up of β (1-4)-linked D-glucose units). Chitosan is the N-deacetylated derivative of chitin, although this N-deacetylation is never complete, which has a number of amino groups exposed making it

polycationic polysaccharide. Depending on the amount/extent of deacetylation, different grades of chitosan are found. Due to its gel-forming property, it has been used in the designing of drug delivery system. [14]

Montmorillonite (MMT) clay is one of the smectite group, composed of silica tetrahedral sheets layered between an alumina octahedral sheets. The imperfection of the crystal lattice and the isomorphous substitution induce a net negative charge that leads to the adsorption of alkaline earthmetal ions in the interlayer space. Such imperfection is responsible for the activity and exchange reactions with organic compounds. MMT also contains dangling hydroxyl end-groups on the surfaces [15]. MMT has large specific surface area; exhibits good adsorb ability, cation exchange capacity, stand out adhesive ability, and drug-carrying capability. Thus, MMT is a common ingredient as both the excipient and active substance in pharmaceutical products [16]. The intercalation of organic species into layered inorganic solids provides a useful and convenient route to prepare organic-inorganic hybrids that contain properties of both the inorganic host and organic guest in a single material [17].

In recent years, smectite clays intercalated by drug molecules have attracted great interest from researchers since they exhibit novel physical and chemical properties.[18]. investigated the intercalation of ibuprofen into MMT as a sustained release drug carrier.

In the present work, we successfully intercalate chitosan into layered silicate to prepare nanocomposite drug carrier that would alleviate some of the disadvantages of using clay. The cationic exchange mechanism involves interaction between Ph_3P^+ groups of modified CS and negatively charged sites in the clay structure. The resulting materials were characterized by IR, XRD and TEM. The release rate of Ibuprofen from the nanocomposites, Na-MMT and CS was investigated. We studied the antimicrobial activity of ibuprofen loaded CS-MMT nanocomposites.

Characterization of organo-clay/drug.

XRD spectra.

The XRD patterns of Ibuprofen, Na-MMT, chitosan, mod-CS/MMT (1:1), mod-CS/MMT (1:1)/ Ibuprofen, Na-MMT /Ibuprofen and CS/ Ibuprofen are shown in Figure 1 (a-c). Pure Ibuprofen exhibits typical reflection at $2\theta=6.06^\circ$, 16.65° and 22.28° , corresponding d_{001} are 1.46, 0.53, 0.40 nm respectively. Na-MMT exhibits typical reflection at $2\theta = 9.6^\circ$ corresponding to d_{001} is 9.6 Å. CS shows the characteristic crystalline peaks around $2\theta = 10, 20, 22^\circ$. The peaks around 10 and 20 are related to crystal (1) and crystal (2) in chitosan respectively. The unit cell of crystal (1) is characterized by $a=7.76$, $b=10.91$, $c=10.30$ Å and $\beta=90^\circ$ and it is larger than that of crystal (2), whose unit cell is characterized by $a=4.4$, $b=10.0$, $c=10.3$ Å and $\beta=90^\circ$ [19, 20]. After modification of chitosan, mod-CS showed two sharp peaks at $2\theta = 12, 15^\circ$

and a broad peak at $\sim 22^\circ$. This indicates that mod-CS formed a new crystallite. In mod-CS/MMT (1:1) the d_{001} peak of the clay has been disappeared and a broad peak at $2\theta = 4^\circ$, appeared corresponding to an increase in d-spacing. This increase in basal spacing is attributable to the intercalation of polymer chain inside the clay layers. The low peak intensity in the nanocomposite is because of the decrease in coherent layer scattering.

The XRD of the nanocomposite formed after loading ibuprofen on Na-MMT, chitosan, mod-CS/MMT (1:1) showed peaks characteristic for both ibuprofen and support. Table 1 and the intensity of the (001) reflection the intercalation of ibuprofen. And present of some unintercalated Ibuprofen crystallized on the surface of the support.




Figure 1. X-ray diffraction pattern of **A)** Na-MMT, CS, mod-CS, mod-CS/MMT (1:1), Ibuprofen, mod-CS/MMT –Ibuprofen on cold. **B).** Na-MMT, CS, mod-CS, mod-CS/MMT (1:1), Ibuprofen, mod-CS/MMT –Ibuprofen on hot. **C).** Ibuprofen, CS, CS/Ibuprofen and after release at Ph=5.4 and 7.8.

TEM result

TEM of a thin film of mod-CS/MMT (1:1) Ibuprofen (solvent method on cold) and mod-CS/MMT (1:1) ibuprofen (solvent method on cold) are shown in (Fig. 2 (a-b)) respectively. (Fig. 2a) show that silicate

layers remain in exfoliated structure in mod-CS/MMT(1:1)Ibuprofen on cold. However, it is observed that few layers remain in intercalated structure in mod-CS/MMT (1:1) Ibuprofen prepared by solvent method on hot. This is consistent with the conclusion drawn from XRD.




Figure 2: TEM micrographs of **a).** M.chitosan-MMT/Ibuprofen (1:1) on cold **.b).** M.chitosan-MMT/Ibuprofen (1:1) on hot .

IR spectrum.


The IR spectrum in Fig (3 a-c) of Ibuprofen the strong carbonyl absorption band at 1721 cm^{-1} , the bands between 3700 and 3100 cm^{-1} are related to the aromatic ring. The bands between 3000 and 2800 cm^{-1} are the alkyl stretching vibration of Ibuprofen. for Na-MMT characteristic absorption band at 3632 cm^{-1} [ν (O-H)] is assigned to the

stretching vibration of Al-OH. The symmetrical Si-O-Si band [ν (Si-O-Si)] is characterized by the stretching band at 1160 cm^{-1} . Other characteristic adsorption bands of pure clay mineral are at 914 [δ (Al-Al-O)], 886 [δ (Al-Fe-O)] and 848 cm^{-1} [δ (Al-Mg-O)]. IR spectrum of CS shows a broad band at 3462 cm^{-1} corresponding to the stretching vibration

of N-H. The peak at 2937 and 2857 cm^{-1} are typical of C-H stretch vibration, While peaks at 1660, 1551 and 1309 cm^{-1} are characteristic of amides I, II and III respectively. The sharp peaks at 1442 and 1374 cm^{-1} are assigned to the CH_3 symmetrical deformation mode and 1036 cm^{-1} is indicative of C-O stretching vibration [ν (C-O-C)]. The small peak at $\sim 798 \text{ cm}^{-1}$ corresponds to wagging of the saccharide structure of CS. The IR spectrum of mod-CS shows a band at 1740, 1615 cm^{-1} corresponding to C=O stretching vibration, NH- respectively. The bands at 1421 (m), 1164

Sci. Res. Impact 010

(m) and 1063 cm^{-1} (w) corresponding to phosphonium salt attached to Ph group. Not all characteristic bands belonging to MMT and Ibuprofen appear in the spectrum of Ibuprofen/MMT, several new absorption bands at 2390 and 1558 cm^{-1} are also recognized. This also indicates that Ibuprofen interacts strongly with the montmorillonite layers.



C





Figure 3: IR.spectra in the region 4000-400 cm^{-1} of **a**). Na-MMT, CS, mod-CS, mod-CS/MMT (1:1), Ibuprofen, mod-CS/MMT – Ibuprofen on cold. **b** Na-MMT, CS, mod-CS, mod-CS/MMT (1:1), Ibuprofen, mod-CS/MMT –Ibuprofen on hot. **c**). Ibuprofen, CS, CS/Ibuprofen and after release at Ph=5.4 and 7.8.

2.4. Thermal stability.

The TGA curves **Figure 5**. of montmorillonite show two distinct steps. The first one of about 7% at 48–120 °C is due to the free water evaporation. The second weight loss at 550–720 °C is due to the structural dehydration [21]. In the curve of

mod-CS, mod- CS –MMT and mod- CS – MMT\Ibuprofen weight loss at 100 to 400 °C corresponds to the decomposition of Ibuprofen. Other weight losses are the same with those of MMT. The TGA curve of mod- CS –MMT\Ibuprofen on cold with an initial concentration of 0.3 mmol/g (drug-loaded amount 36.09 wt.%) while mod- CS –MMT\Ibuprofen on hot with same initial concentration (drug-loaded amount 15.12 wt.%) shows a sharp weight loss at around 471 °C due to the decomposition of intercalated Ibuprofen.



Code of nano composite	Wt at pH=7.8	Wt at pH=5.4
Mod-CS/MMT (1:1)-Ibuprofen on hot	3.05×10^{-5}	2.31×10^{-5}
Mod-CS/MMT (1:1)-Ibuprofen on cold	2.77×10^{-5}	1.25×10^{-5}
CS-Ibuprofen	50.7×10^{-5}	83.4×10^{-5}

Figure 4. TGA of mod-CS, mod-CS/MMT (1:1), mod-CS/MMT –Ibuprofen prepared by solvent method A) on cold and B) on hot

Drug release response.

The drug release response from mod-CS/MMT nanocomposite in buffer solution

with two different pH values 5.4 and 7.4 was studied at the physiological temperature of 37 °C (Fig. 6a-b). The swellability of

the carrier in the buffer solution The swelling ratio for mod-CS/MMT (2.5:1) in table indicate that the great swellability the greater the release is shown in **Table 1**.

Table 3: Swellability of the carriers in different pH buffer solutions.

Ibuprofen, a relatively weak acidic drug, was intercalated into mod-CS/MMT and CS. The in vitro release experiment showed that the release of Ibuprofen from mod-CS/MMT\Ibuprofen and CS\Ibuprofen was affected by the pH value of the dispersion. The release rate in simulated intestinal fluid (pH=7.4) was noticeably higher than that in simulated gastric (pH=5.4). The release of IBU from IBU/MMT was affected by the pH value of the

dispersion. The release rate in simulated intestinal fluid (pH=7.4) was noticeably higher than that in simulated gastric (pH=1.2). The results indicate that MMT can be used as the sustained-release carrier of IBU in oral administration. The results indicate that mod-CS/MMT can be used as the sustained-release carrier of Ibuprofen in oral administration. Allows minimum effective dose to be delivered locally (subcutaneous) and prolongs the duration of drug activity, thus improves the therapeutic efficacy and decreases side effects by minimizing the transportation of the drug to the systemic circulation against inflammation. [22] Minimizes the adverse effect of oral administration and avoid contact between the drug and the gastric mucosa. [23].




Figure 5. *In vitro* Ibuprofen release in phosphate buffer solution A- (pH = 7.8) and B- (pH = 5.4) at 37°C. from **A-B)** mod-CS/ MMT- Ibuprofen (1:1) by different method. **C)** CS/Ibuprofen

Characterization of the support after release.

The drug carrier nanocomposites were further subjected to examination by IR, XRD after drug release. The IR spectra of mod-CS/MMT/Ibuprofen after release Figure 3 indicates that the peaks characteristic to mod-CS, Ibuprofen disappeared and bands characteristic to Na-MMT is observed. These observations suggest that the

drug release occurred by degradation of the nanocomposites. XRD of samples after release has no visible diffraction peak within the range measured. The peak at $2\theta \approx 20^\circ$ appearing in all the diffraction patterns corresponding to the crystallographic plan (110) and (020) of the clay layers disappeared after release and an amorphous structure is obtained Figure 6 especially after immersion the carrier at pH 7.8.




Figure 6. X-ray diffraction pattern of mod-CS, mod-CS/MMT (1:1), Ibuprofen, mod-CS/MMT – Ibuprofen on cold after release.

Experimental

Materials

Chitosan from a shell of *Chionocetes opilio*. It has 70 % degree of deacetylation with average molecular weight of 400.000 was purchased from Aldrich chemicals. Ibuprofen, triphenyl phosphine

and chloroacetylchloride provided from Aldrich chemicals. The clay mineral used in this study was sodium montmorillonite (Colloid BP) from Southern Clay Products Inc (Gonzales, Texas, USA) with cation exchange capacity (CEC) of 114.8 meq/100g. The structure of CS and Ibuprofen is shown in (Figure 7)




Figure 7. Structure of CS and Ibuprofen.

Chloroacetylation of chitosan.

75.2 ml (99.6 mmol) of pyridine were added to 1g chitosan. The mixture was cooled in an ice-salt bath and chloroacetyl chloride (7.965 ml, 99.6 mmol) was added drop wise with stirring. The reaction mixture was stirred overnight at 40 °C for three days. The chloroacetylated chitosan was precipitated by addition of dilute HCl (1N), filtered off and washed with distilled water several times and the product was dried to give 0.95g.

Synthesis of Triphenyl-chloro acetylated chitosan phosphonium salt (mod-CS).

2g of chloro acetylated chitosan was dissolved in 20 ml dry DMF followed by addition of 5.33g (20 mmol) triphenyl phosphine. The reaction mixture was stirred for four days at 80 °C in an oil bath. The product was filtered off, washed with DMF to give 1.5g.

Preparation of Triphenyl- (chloro acetylated chitosan) phosphonium salt-

montmorillonite intercalates (mod-CS/MMT).

1g of Na-MMT was swelled in 30 ml water by stirring several hours at 40°C. After swelling of clay 1g mod-CS dissolved in 10 ml DMF was added and stirred for 24 hr. The product (mod-CS/MMT (1:1)) was filtered, washed several times with water and collected by a filter press and dried at 80 °C in vacuum oven for 10 hr.

Loading of Ibuprofen by Solvent method.

Loading of Ibuprofen on modified chitosan

0.3g Ibuprofen in 10 ml DMF was added to 0.5g of mod-CS/MMT (1:1) swelled in 30 ml DMF with stirring for 24 hr. The product was filtered, washed several times with water and collected by a filter press and dried at 80°C in vacuum oven for 10 hr. The same procedure was done by applying temperature (80°C) to improve the absorption between the drug and Mod-CS.

Loading of Ibuprofen on Na-MMT.

1g of Na-MMT was swelled for 48 hrs at 40°C in DMF. Then, 5g of Ibuprofen dissolved in DMF was added. The reaction mixture was further stirred for more 24 h at 40°C. The product (Na-MMT/Ibuprofen) was collected by filtration and washed with ethanol (three times) to remove the excess of unloaded drug and dried under vacuum at 40°C overnight.

Loading of Ibuprofen on CS.

1g of CS was dissolved in 2% acetic acid then, 0.3g of Ibuprofen dissolved in 10 ml DMF was added. The reaction mixture was further stirred for more 24 h at 40°C. The product (CS-Ibuprofen) was collected by filtration and washed with ethanol (three times) to remove the excess of unloaded drug and dried under vacuum at 40°C overnight.

Drug Release.

Preparation of Phosphate buffer (PB) solution.

Phosphate buffer solution (PB) was prepared by dissolving sodium phosphate dibasic (21.7g) and potassium phosphate monobasic (2.6g) in 1L deionized water and the pH was adjusted to 5.4 and 7.8 using 0.1N sodium hydroxide or 0.1N hydrochloric acid respectively.

***In vitro* Drug Release.**

The drug release responses of CS, Na-MMT and mod-CS/MMT drug carriers were studied at the physiological temperature of 37±0.5 °C and pH 5.4 and 7.8. The pH values of 5.4 and 7.8 were selected to closely mimic the pH gradient from the stomach to the intestine. In

each experiment 10 mg of the drug carriers was submerged in 50 ml buffer solution. An aliquot of the release medium (3ml) was withdrawn at regular time for 72 h. The content of Ibuprofen in buffer solution was quantified using UV-VIS spectrophotometry at $\lambda_{max} = 265$ nm. After each measurement, the withdrawn was put back into the system. Given that the measurement time was very short, while the predetermined drug release time interval was significantly larger, the influence of the returned medium on drug release during the measurement time was insignificant. All the drug release experiments were repeated three times and the average was calculated.

Swelling measurements.

The samples were weighed in a sintered glass, W_1 and immersed in buffer solution (pH=5.4 and 7.8) at 37°C. The samples were centrifuged to remove the surface buffer solution and reweighed immediately, W_2 . The process was repeated at the same time intervals used in measurement of *in vitro* drug release. The swellability percentage was calculated using the formula $(W_2 - W_1 / W_1) \times 100$.

Conclusions.

Modified chitosan/MMT nanocomposite was successfully synthesized. It entails two steps: modification of chitosan by chloroacetylation and formation of phosphonium salt, which is then chemically intercalated to MMT through an ion exchange process. The resulting nanocomposite was used as support for Ibuprofen. The release of Ibuprofen from support is affected by the drug

loading capacity, the percentage of CS in the nanocomposite, the pH of the medium and the morphology of the nanocomposites, which is affected by the method of preparation.

The drug loaded chitosan and mod-chitosan can be of immense importance in the drug delivery through the oral route as well as the other routes as sustained and controlled release dosage forms. The desired effects in the drug release and the therapeutic value can be obtained by intercalated ibuprofen in

different temperature. As chitosan is nontoxic, biodegradable, biocompatible, it can be used for the delivery of the ibuprofen in controlled and sustained release manners.

Acknowledgements:

The authors wish to thank the king Khalid university for supporting this research.

Reference:

1. Wilson, C.G.; Washington, N.; Greaves, J.L.; Kamali, F.; Rees, J.A.; Sempik, A.K.; Lampard, J.F. Bimodal release of ibuprofen in a sustained-release formulation. A scintigraphic and pharmacokinetic open study in healthy volunteers under different conditions of food intake. *International Journal of Pharmaceutics*. 1989, 50,155–161.
2. Goodman Gilman,s.; Goodman, L.S.; Rall, T.W.; Murad, F. *The pharmacological basis of therapeutics*. 7th ed. New York: Macmillan Publishing Company. 1985.
3. Diamantis, W.; Melton, J.; Sofia, R.D.; Ciofalo, V.B. Comparative gastric ulcerogenic effects of meseclazone, 5-chlorosalicylic acid and other nonsteroidal anti-inflammatory drugs following acute and repeated oraladministration to rats. *Toxicology and Applied Pharmacology*. 1980, 52, 454–461.
4. Bodmeier, R.; Chen, H. Preparation and characterization of microspheres containing the anti-inflammatory agents indomethacin, ibuprofen, and ketoprofen. *Journal of Controlled Release*. 1989, 10, 167–175.
5. Bakan, J.A.; Powell, T.C.; Szotac, P.S.. Recent advances imicroencapsulation of drugs to obtain reduced gastric irritation. In: Donbrow M, editor. *Microcapsules and nanocapsules in medicine and pharmacy*. Boca Raton, FL. 1992, CRC Press, 183–192.
6. Leo, E.; Forni, F.; Bernabei, M.T. Surface drug removal from ibuprofen-loaded PLA microspheres. *International Journal of Pharmaceutics*. 2000, 196,1–9.164 B. Arica et al.
7. Sipahigil, O.; Dortunc, B. Preparation and in vitro evaluation of verapamil HCl and ibuprofen containing carrageenan beads. *International Journal of Pharmaceutics*. 2001, 228, 119–128.

8. Arica, B. C.; Alis, S.; Kas, H.S.; Hincal, A.A. Chitosan microspheres of ibuprofen: evaluation and in vitro characterization. In: Muzzarelli RAA, Muzzarelli C, editors. Chitosan in pharmacy and chemistry. Italy: Atec. 2002b. 71–76.
9. Ladron, G.F.S.; Ragel, C.V.; Vallet-Regi, M. Bioactive glass-polymer materials for controlled release of ibuprofen. *Biomaterials*. 2003, 24, 4037–4043.
10. Saravanen, M.; Bhaskar, K.; Srinivasa, R.G.; Dhanaraju, M.D. Ibuprofen-loaded ethylcellulose/polystyrene microspheres: an approach to get prolonged drug release with reduced burst effect and low ethylcellulose content. *Journal of Microencapsulation*. 2003, 20, 289–302.
11. Segi, N.; Yotsuyanagi, T.; Ikeda, K. Interaction of calcium-induced gelation of alginic acid and pH-sensitive reswelling of dried gels. *Chemical Pharmaceutical Bulletin*. 1989, 37, 3092–3095.
12. C, alis, S.; Arica, B.; Atılla, P.; Durlu, T. C.; akar, N.; Hincal, A.A. Effect of ibuprofen and ibuprofen incorporated biodegradable alginate beads on gastric and duodenal mucosa (a comparative histological study). *Controlled Release Society 30th Annual Meeting Proceedings*, 2003, 19–23 July, 495-501.
13. Lee, B.J.; Cui, J.H.; Kim, T.W.; Heo, M.Y.; Kim, C.K. Biphasic release characteristics of dual drug-loaded alginate beads. *Archives of Pharmaceutical Research*. 1998, 21, 645–650.
14. Wong, T.W.; Chan, L.W.; Kho, S.B.; Heng, P.W.S. Design of controlled release solid dosage forms of alginate and chitosan using microwave. *J Control Release*. 2002, 84, 99-114.
15. Khalil, H.; Mahajan, D.; Rafailovich, M.; Polymer–montmorillonite clay nanocomposites. Part 1: complexation of montmorillonite clay with a vinyl monomer. *Polym. Int*. 2005, 54, 423–427.
16. Wang, X.; Du, Y.; Luo, J. Biopolymer/montmorillonite nanocomposite: preparation, drug-controlled release property and cytotoxicity. *Nanotechnology*. 2008, 19, 065707.
17. Mohanambe, L.; Vasudevan, S. Anionic clays containing anti-inflammatory drug molecules: comparison of molecular dynamics simulation and measurements. *J. Phys. Chem. B*. 2005, 109, 15651–15658.
18. Zheng, J.P.; Luan, L.; Wang, H.Y.; Xi, L.F.; Yao, K.D. Study on ibuprofen/montmorillonite intercalation composites as drug release system. *Appl. Clay Sci*. 2007, 36, 297-304.
19. Samuels, R. J. Solid state characterization of the structure of chitosan film, *J. Polym Sci Polym Phys Ed*. 1981, 19, 1081-1105.
20. Ogawa, K.; Yui, T.; Miya, M. Dependence on the Preparation Procedure of the Polymorphism and Crystallinity of Chitosan Membranes, *Biosci Biothechnol Biochem*. 1992, 56(6), 858-62.
21. Hutchison, C. S. *Laboratory Hand book of petrographic techniques*. New York : McGraw-Hill Book Co. 1973, 456-62.
22. Kofuji, K.; Akamine, H.; Qian, C.J.; Watanabe, K.; Togan, Y.; Nishimura, M.; Sigiyama, I.; Murata, Y.; Kawashima, S. Therapeutic efficacy of sustained drug release from chitosan gel on local inflammation. *Int J Pharm*. 2004, 272, 65-78

23. Gonzalez-Rodriguez, M.L.; Holgado, M.A.; Sanchez-Lafuente, C.; Rabasco, A.M.; Fini, A. Alginate/chitosan particulate systems for sodium diclofenac release. *Int J.Pharm.*2002, 232, 225-234